Repatha ® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets

New Analysis From Cardiovascular Outcomes Trial Shows Addition of Repatha in Patients Considered at Goal Further Reduces Cardiovascular Event Risk Separate Analysis Demonstrates Consistent Cardiovascular Risk Reduction in Patients Even on Maximum-Intensity Statin Therapy THOUSAND OAKS, Calif., May 20, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Repatha® (evolocumab) cardiovascular outcomes trial (FOURIER), which showed that Repatha consistently and safely reduced cardiovascular events in patients with established cardiovascular disease regardless of baseline low-density lipoprotein cholesterol (LDL-C) level below or above 70 mg/dL. A separate analysis al...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news